Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

How Is AbbVie's Stock Performance Compared to Other Pharmaceuticals Stocks?

North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With a market cap of $323.4 billion, the company discovers and develops medicines and therapies that solve health issues across immunology, oncology, aesthetics, neuroscience, and eye care. 

Companies worth $200 billion or more are generally described as “mega-cap stocks,” and ABBV definitely fits that description, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the general drug manufacturers industry. ABBV stands out in the fields of immunology and oncology with its extensive product portfolio, featuring leading drugs like Humira, Imbruvica, and Rinvoq,...

Fundamentals

See More
  • Market Capitalization, $K 699,116,416
  • Shares Outstanding, K 947,736
  • Annual Sales, $ 45,043 M
  • Annual Income, $ 10,590 M
  • EBIT $ 14,085 M
  • EBITDA $ 15,852 M
  • 60-Month Beta 0.48
  • Price/Sales 15.20
  • Price/Cash Flow 50.76
  • Price/Book 43.21

Options Overview Details

View History
  • Implied Volatility 42.25% ( +1.20%)
  • Historical Volatility 64.29%
  • IV Percentile 92%
  • IV Rank 47.05%
  • IV High 64.53% on 04/07/25
  • IV Low 22.46% on 06/28/24
  • Put/Call Vol Ratio 0.40
  • Today's Volume 75,682
  • Volume Avg (30-Day) 68,104
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 478,669
  • Open Int (30-Day) 373,941

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 5.54
  • Number of Estimates 8
  • High Estimate 6.00
  • Low Estimate 5.24
  • Prior Year 3.92
  • Growth Rate Est. (year over year) +41.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
709.00 +4.04%
on 05/23/25
850.93 -13.31%
on 05/01/25
-161.28 (-17.94%)
since 04/30/25
3-Month
677.09 +8.95%
on 04/07/25
935.63 -21.16%
on 03/03/25
-182.96 (-19.87%)
since 02/28/25
52-Week
677.09 +8.95%
on 04/07/25
972.53 -24.15%
on 08/22/24
-70.19 (-8.69%)
since 05/28/24

Most Recent Stories

More News
Pharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline Updates

This week, Eli Lilly LLY announced plans to acquire SiteOne Therapeutics to expand its pain pipeline. Moderna MRNA announced that the U.S. Department of Health and Human Services (“HHS”) has terminated...

MRK : 76.84 (+0.58%)
LLY : 737.67 (+2.09%)
MRNA : 26.56 (-1.37%)
GSK : 41.03 (+2.58%)
SNY : 49.37 (-5.69%)
2 Top Stocks to Buy With Less Than $100

NVO : 71.50 (+2.94%)
LLY : 737.67 (+2.09%)
EXEL : 43.04 (+1.03%)
3 American Growth Giants to Invest in for the Long Haul

NVDA : 135.13 (-2.92%)
LLY : 737.67 (+2.09%)
PANW : 192.42 (+3.55%)
How Is AbbVie's Stock Performance Compared to Other Pharmaceuticals Stocks?

AbbVie has outperformed the Pharmaceuticals industry over the past year, and analysts are moderately optimistic about the stock’s prospects.

PJP : 79.98 (+0.05%)
LLY : 737.67 (+2.09%)
ABBV : 186.11 (+0.26%)
2 Beaten-Down Stocks to Buy on the Dip

NVO : 71.50 (+2.94%)
CAVA : 81.27 (-0.74%)
LLY : 737.67 (+2.09%)
Looking for a Blend of Growth and Dividend Stocks Amid Market Uncertainty? Consider This Low-Cost Vanguard ETF.

MSFT : 460.36 (+0.37%)
AAPL : 200.85 (+0.45%)
AVGO : 242.07 (+0.04%)
KO : 72.10 (+0.85%)
VIG : 197.93 (+0.30%)
$SPX : 5,911.69 (-0.01%)
VOO : 541.76 (-0.10%)
LLY : 737.67 (+2.09%)
VUG : 413.14 (-0.09%)
VTV : 171.39 (+0.16%)
PEP : 131.45 (-0.36%)
Is Merck Stock Underperforming the Nasdaq?

Despite Merck’s recent underperformance relative to the Nasdaq, analysts remain moderately optimistic about the stock’s prospects.

$NASX : 19,113.77 (-0.32%)
MRK : 76.84 (+0.58%)
LLY : 737.67 (+2.09%)
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.

LLY : 737.67 (+2.09%)
Is Eli Lilly and Company Stock Underperforming the Dow?

While Eli Lilly has underperformed the Dow over the past year, analysts remain bullish about the stock’s prospects.

JNJ : 155.21 (+1.06%)
LLY : 737.67 (+2.09%)
$DOWI : 42,270.07 (+0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 778.80
2nd Resistance Point 762.35
1st Resistance Point 750.01
Last Price 737.67
1st Support Level 721.22
2nd Support Level 704.77
3rd Support Level 692.43

See More

52-Week High 972.53
Fibonacci 61.8% 859.67
Fibonacci 50% 824.81
Fibonacci 38.2% 789.95
Last Price 737.67
52-Week Low 677.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar